CRISPR/Cas9-gene therapy (University of Bielefeld)

N/A

Report date: 2025/03/19 08:59:19

Base Information

Drug NameCRISPR/Cas9-gene therapy (University of Bielefeld)
Drug Alias Namedual IKK CRISPR/Cas9-gene therapy (University of Bielefeld)
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy
Mechanisms of ActionElongator complex protein 1 inhibitorsInhibitor of nuclear factor kappa-B kinase subunit beta inhibitors
TargetsElongator complex protein 1Inhibitor of nuclear factor kappa-B kinase subunit beta
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Bielefeld
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of BielefeldPROvendis GmbH
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A